Tenax Therapeutics to Release Phase 3 Heart Failure Trial Results Soon
Tenax Therapeutics announced that it will soon disclose data from its Phase 3 trial of a heart-failure treatment.
The study is being watched as one of the largest binary events left for biotech stocks this year, meaning the outcome could sharply affect the company’s valuation.
Investors and industry analysts are awaiting the results, which are expected later in the year, to gauge the therapy’s potential impact on the heart-failure market.
The pending readout underscores the importance of late-stage trial data in shaping the biotech investment landscape.
This writeup was produced by pharmadog from original reporting by STAT. The original article may no longer be reachable at its published URL.
Original headline: “STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment”
read at STAT ↗
comments(0)
5-min edit window · permanent after that